Status:
COMPLETED
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Advanced Solid Tumors
Metastatic Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
A Phase I dose escalation study to determine the safety, tolerability, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in combination with chemotherapy drugs, paclitaxel and carbopl...
Eligibility Criteria
Inclusion
- Subjects with advanced or metastatic solid tumors for whom carboplatin and paclitaxel is considered an appropriate therapy
- ECOG performance status 0-1
- At least 4 weeks between surgery or last dose prior anti-cancer therapy
Exclusion
- Symptomatic brain metastases
- Any disorder or dysregulation of glucose homeostasis {e.g. diabetes)
- Uncontrolled or significant cardiovascular disease
- Inadequate bone marrow, liver or kidney function
- Evidence of \> Grade 1 peripheral neuropathy
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00793897
Start Date
April 1 2009
End Date
June 1 2012
Last Update
July 13 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
East Melbourne, Victoria, Australia, 3002
2
Local Institution
Parville, Victoria, Australia, 3050
3
Local Institution
Edmonton, Alberta, Canada, T6G 1Z2
4
Local Institution
Hamilton, Ontario, Canada, L8V 5C2